Recipharm expands Swedish facility; FDA warns Chinese OTC maker; DSM, Indoco ink pact;

> Sweden's Recipharm will expand capacity of its analytical services and stability studies at its facility in Solna, Sweden. Release

> The FDA has warned Shanghai Huhui Daily Use Chemical Products that its products may be refused entry into the U.S. until it fixes a host of problems inspectors found at its manufacturing plant in Shanghai. Warning Letter

> India-based packaging company ACG Worldwide is plunking down about $71 million in the phased construction of a new manufacturing plant at Pithampur, Indore, India. Item

> DSM Pharmaceuticals has struck a deal with Indian API maker Indoco Remedies to sell 8 of its active pharmaceutical ingredients. Item

And Finally... With the patent cliff ending for branded drugmakers, the fiscal precipice now looms for generics makers. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.